Immunovant stock shot to a two-year high Wednesday on "highly compelling" results for its experimental rheumatoid arthritis treatment.

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies ...

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...

On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity ...

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Top 10 mid-cap stocks by YTD performance amid market volatility—see 600%+ gainers across semis, biotech & more, plus mid-cap ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

Biotech stocks tied to cancer, autoimmune and rare disease therapies gain attention as M&A activity boosts sector sentiment.

Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified ...

This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.